PulseAugur
中
实时 15:44:23
English(EN) Exclusive: Former OpenAI exec Fidji Simo discusses her battle with POTS and her startup’s plans to cure it with AI and 3,500 vials of blood (so far)

前OpenAI高管创办AI初创公司ChronicleBio以治愈慢性疾病

前OpenAI高级执行官Fidji Simo已创办ChronicleBio,一家专注于利用AI寻找体位性心动过速等慢性疾病治愈方法的初创公司。该公司已收集了近700名患者的3500多份血液样本,并提取了153太字节的数据,这远超训练GPT 3.5所用的数据量。ChronicleBio已筹集1500万美元,并计划提供居家抽血服务,以收集更多生物数据用于AI驱动的药物发现和临床试验改进。 AI

影响 可能加速AI在慢性病个性化医疗和药物发现领域的应用。

排序理由 知名AI实验室前高管创办一家新的AI驱动生物技术公司。[lever_c_降级为显著:ic=1 ai=0.7]

在 Fortune 阅读 →

AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →

前OpenAI高管创办AI初创公司ChronicleBio以治愈慢性疾病

本文如何被排名

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
知名AI实验室前高管创办一家新的AI驱动生物技术公司。[lever_c_降级为显著:ic=1 ai=0.7]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
57 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

报道来源 [1]

  1. Fortune TIER_1 English(EN) · Emily Forlini ·

    独家:前OpenAI高管Fidji Simo谈她与POTS的斗争以及她的初创公司计划用AI和迄今为止3500份血液样本来治愈它

    Simo is a cofounder of ChronicleBio, which aims to cure complex chronic diseases by analyzing biological data with the latest AI models.